Go or no go? Apellis and Heron head for the finish line
May will see US FDA decisions for Apellis, Heron and Bristol Myers Squibb, while Provention Bio is set for a panel meeting.
Go or no go? Pandemic looms over FDA timelines
Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.